CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Karuna Therapeutics, Inc. - KRTX CFD

    329.60
    0.03%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    Trading сonditions
    Spread 0.41
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026179 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026179%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003957 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003957%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Karuna Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 329.51
    Open* 329.63
    1-Year Change* 75.95%
    Day's Range* 329.56 - 329.7
    52 wk Range 158.38-319.42
    Average Volume (10 days) 1.26M
    Average Volume (3 months) 14.59M
    Market Cap 11.97B
    P/E Ratio -100.00K
    Shares Outstanding 37.89M
    Revenue 5.93M
    EPS -10.93
    Dividend (Yield %) N/A
    Beta 1.20
    Next Earnings Date Feb 21, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Mar 15, 2024 329.60 0.03 0.01% 329.57 329.76 329.54
    Mar 14, 2024 329.51 -0.05 -0.02% 329.56 329.59 329.41
    Mar 13, 2024 321.75 -0.98 -0.30% 322.73 322.81 320.58
    Mar 12, 2024 322.12 2.81 0.88% 319.31 322.12 319.11
    Mar 11, 2024 319.00 0.24 0.08% 318.76 319.81 318.06
    Mar 8, 2024 319.49 2.23 0.70% 317.26 319.55 317.26
    Mar 7, 2024 317.25 -0.56 -0.18% 317.81 319.31 316.59
    Mar 6, 2024 318.22 0.22 0.07% 318.00 319.55 316.48
    Mar 5, 2024 318.43 0.67 0.21% 317.76 319.05 317.18
    Mar 4, 2024 317.86 3.05 0.97% 314.81 318.02 314.81
    Mar 1, 2024 315.98 2.20 0.70% 313.78 316.75 313.78
    Feb 29, 2024 313.69 -1.12 -0.36% 314.81 315.91 313.69
    Feb 28, 2024 315.34 1.03 0.33% 314.31 316.55 314.31
    Feb 27, 2024 314.65 -0.11 -0.03% 314.76 317.83 313.88
    Feb 26, 2024 315.69 -3.62 -1.13% 319.31 319.83 295.80
    Feb 23, 2024 320.06 2.83 0.89% 317.23 320.19 317.23
    Feb 22, 2024 319.06 1.00 0.31% 318.06 319.26 318.06
    Feb 21, 2024 318.70 1.29 0.41% 317.41 318.72 317.41
    Feb 20, 2024 318.20 0.89 0.28% 317.31 318.80 317.31
    Feb 16, 2024 318.06 -0.70 -0.22% 318.76 319.60 317.22

    Karuna Therapeutics, Inc. Events

    Time (UTC) Country Event
    Thursday, May 2, 2024

    Time (UTC)

    12:30

    Country

    US

    Event

    Q1 2024 Karuna Therapeutics Inc Earnings Release
    Q1 2024 Karuna Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    Wednesday, June 19, 2024

    Time (UTC)

    13:00

    Country

    US

    Event

    Karuna Therapeutics Inc Annual Shareholders Meeting
    Karuna Therapeutics Inc Annual Shareholders Meeting

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 10.637 36.964 0 0 0
    Revenue 10.637 36.964 0 0 0
    Total Operating Expense 300.313 181.519 71.816 45.405 14.51
    Selling/General/Admin. Expenses, Total 76.066 52.617 28.408 20.869 2.974
    Research & Development 224.247 128.2 43.408 24.536 11.536
    Operating Income -289.676 -144.555 -71.816 -45.405 -14.51
    Interest Income (Expense), Net Non-Operating 14.178 0.502 3.305 1.448 -3.002
    Net Income Before Taxes -274.918 -143.799 -68.511 -43.957 -17.512
    Net Income After Taxes -276.336 -143.805 -68.554 -43.957 -17.512
    Net Income Before Extra. Items -276.336 -143.805 -68.554 -43.957 -17.512
    Net Income -276.336 -143.805 -68.554 -43.957 -17.512
    Income Available to Common Excl. Extra. Items -276.336 -143.805 -68.554 -43.957 -17.512
    Income Available to Common Incl. Extra. Items -276.336 -143.805 -68.554 -43.957 -17.512
    Diluted Net Income -276.336 -143.805 -68.554 -43.957 -17.512
    Diluted Weighted Average Shares 31.629 29.1389 26.446 26.0128 21.3729
    Diluted EPS Excluding Extraordinary Items -8.73679 -4.93515 -2.59223 -1.68982 -0.81935
    Dividends per Share - Common Stock Primary Issue 0
    Diluted Normalized EPS -8.73679 -4.91949 -2.59223 -1.68982 -0.81935
    Unusual Expense (Income) 0 0.702
    Other, Net 0.58 0.254
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0.654 5.278 0.081 5.278
    Revenue 0 0.654 5.278 0.081 5.278
    Total Operating Expense 119.907 109.72 90.314 81.075 70.33
    Selling/General/Admin. Expenses, Total 27.417 24.253 24.31 19.125 17.843
    Research & Development 92.49 85.467 66.004 61.95 52.487
    Unusual Expense (Income) 0 0 0
    Operating Income -119.907 -109.066 -85.036 -80.994 -65.052
    Interest Income (Expense), Net Non-Operating 16.597 11.345 9.567 3.884 0.49
    Net Income Before Taxes -103.163 -97.574 -75.322 -76.963 -64.415
    Net Income After Taxes -103.163 -97.574 -76.212 -76.963 -64.943
    Net Income Before Extra. Items -103.163 -97.574 -76.212 -76.963 -64.943
    Net Income -103.163 -97.574 -76.212 -76.963 -64.943
    Income Available to Common Excl. Extra. Items -103.163 -97.574 -76.212 -76.963 -64.943
    Income Available to Common Incl. Extra. Items -103.163 -97.574 -76.212 -76.963 -64.943
    Diluted Net Income -103.163 -97.574 -76.212 -76.963 -64.943
    Diluted Weighted Average Shares 37.5246 34.8006 34.4367 32.3491 29.8963
    Diluted EPS Excluding Extraordinary Items -2.74921 -2.8038 -2.2131 -2.37914 -2.17227
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -2.74921 -2.8038 -2.2131 -2.37914 -2.17227
    Other, Net 0.147 0.147 0.147 0.147 0.147
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 1154.77 517.334 344.599 392.706 15.596
    Cash and Short Term Investments 1124.04 493.991 322.33 389.397 13.887
    Cash & Equivalents 248.329 206.953 53.048 208.929 8.904
    Short Term Investments 875.715 287.038 269.282 180.468 4.983
    Prepaid Expenses 27.757 20.43 20.776 2.824 1.686
    Other Current Assets, Total 2.911 1.163 1.493 0.485 0.023
    Total Assets 1163.33 527.671 347.625 393.024 15.857
    Property/Plant/Equipment, Total - Net 7.875 9.545 2.869 0.195 0.138
    Property/Plant/Equipment, Total - Gross 9.555 10.117 3.071 0.252 0.145
    Accumulated Depreciation, Total -1.68 -0.572 -0.202 -0.057 -0.007
    Other Long Term Assets, Total 0.69 0.792 0.157 0.123 0.123
    Total Current Liabilities 33.946 20.213 6.853 2.958 1.196
    Accounts Payable 2.379 1.939 0.865 0.547 0.269
    Accrued Expenses 31.567 18.274 5.988 2.411 0.538
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0
    Other Current Liabilities, Total 0 0.389
    Total Liabilities 37.096 25.645 8.694 3.108 3.814
    Total Long Term Debt 0 0 0 0 2.516
    Long Term Debt 0 2.516
    Other Liabilities, Total 3.15 5.432 1.841 0.15 0.102
    Total Equity 1126.24 502.026 338.931 389.916 12.043
    Redeemable Preferred Stock 0 0 0 0
    Preferred Stock - Non Redeemable, Net 41.965
    Common Stock 0.003 0.003 0.003 0.003 0
    Additional Paid-In Capital 1693.73 790.391 482.955 465.42 1.633
    Retained Earnings (Accumulated Deficit) -564.207 -287.871 -144.066 -75.512 -31.555
    Total Liabilities & Shareholders’ Equity 1163.33 527.671 347.625 393.024 15.857
    Total Common Shares Outstanding 34.4739 29.7706 26.9885 26.0128 21.3729
    Other Equity, Total -3.29 -0.497 0.039 0.005
    Total Receivables, Net 0.057 1.75
    Accounts Receivable - Trade, Net 0.057 1.75
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 1365.4 1451.95 1507.76 1154.77 1219.68
    Cash and Short Term Investments 1341.51 1436.51 1474.45 1124.04 1192.03
    Cash & Equivalents 184.471 263.603 562.66 248.329 628.317
    Short Term Investments 1157.04 1172.91 911.794 875.715 563.717
    Prepaid Expenses 11.462 8.119 25.487 27.757 24.353
    Other Current Assets, Total 12.425 7.318 7.818 2.911 3.21
    Total Assets 1385.1 1472.1 1516.17 1163.33 1228.41
    Property/Plant/Equipment, Total - Net 19.318 19.617 7.93 7.875 8.05
    Other Long Term Assets, Total 0.382 0.539 0.479 0.69 0.684
    Total Current Liabilities 48.968 38.603 25.237 33.946 40.745
    Accounts Payable 2.939 1.102 0.476 2.379 15.716
    Accrued Expenses 45.925 37.501 24.761 31.567 25.029
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.104
    Total Liabilities 62.781 52.54 28.033 37.096 44.457
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 13.813 13.937 2.796 3.15 3.712
    Total Equity 1322.32 1419.56 1488.14 1126.24 1183.95
    Redeemable Preferred Stock 0 0 0 0 0
    Common Stock 0.004 0.004 0.004 0.003 0.003
    Additional Paid-In Capital 2209.3 2188.15 2151.53 1693.73 1675.65
    Retained Earnings (Accumulated Deficit) -884.063 -764.944 -661.781 -564.207 -487.995
    Other Equity, Total -2.929 -3.642 -1.615 -3.29 -3.698
    Total Liabilities & Shareholders’ Equity 1385.1 1472.1 1516.17 1163.33 1228.41
    Total Common Shares Outstanding 37.7194 37.6443 37.398 34.4739 34.346
    Total Receivables, Net 0 0 0 0.057 0.081
    Accounts Receivable - Trade, Net 0 0 0 0.057 0.081
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -276.336 -143.805 -68.554 -43.957 -17.512
    Cash From Operating Activities -228.006 -100.878 -69.856 -30.923 -15.377
    Cash From Operating Activities 1.112 0.506 0.145 0.058 0.006
    Non-Cash Items 42.444 31.576 14.133 12.377 3.985
    Changes in Working Capital 4.774 10.845 -15.58 0.599 -1.856
    Cash From Investing Activities -586.395 -22.688 -89.65 -174.335 -5.115
    Capital Expenditures -0.915 -3.072 -0.419 -0.115 -0.132
    Other Investing Cash Flow Items, Total -585.48 -19.616 -89.231 -174.22 -4.983
    Cash From Financing Activities 855.777 277.575 3.659 405.283 27.577
    Issuance (Retirement) of Stock, Net 856.218 277.858 4.064 404.964 15.877
    Issuance (Retirement) of Debt, Net 0 3.128 11.7
    Net Change in Cash 41.376 154.009 -155.847 200.025 7.085
    Financing Cash Flow Items -0.441 -0.283 -0.405 -2.809
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -97.574 -276.336 -200.124 -123.161 -58.218
    Cash From Operating Activities -100.629 -228.006 -149.249 -89.303 -49.803
    Cash From Operating Activities 0.327 1.112 0.807 0.517 0.248
    Non-Cash Items 8.202 42.444 34.462 23.231 10.921
    Changes in Working Capital -11.584 4.774 15.606 10.11 -2.754
    Cash From Investing Activities -27.491 -586.395 -279.779 12.241 17.796
    Capital Expenditures -0.714 -0.915 -0.625 -0.451 0
    Other Investing Cash Flow Items, Total -26.777 -585.48 -279.154 12.692 17.796
    Cash From Financing Activities 442.451 855.777 850.392 6.205 1.257
    Financing Cash Flow Items -0.119 -0.441 -0.401 -0.069 -0.025
    Issuance (Retirement) of Stock, Net 442.57 856.218 850.793 6.274 1.282
    Net Change in Cash 314.331 41.376 421.364 -70.857 -30.75

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Karuna Therapeutics, Inc. Company profile

    About Karuna Therapeutics Inc

    Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on creating and delivering transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is for the treatment of psychosis in Alzheimer's disease (AD), which is the prevalent subtype of dementia-related psychosis (DRP). KarXT is a combination of xanomeline and trospium. It is advancing a pipeline of therapeutic programs to address the positive, negative and cognitive symptoms associated with schizophrenia and dementia-related psychosis (DRP). Its muscarinic receptors serve a number of physiological roles, including in cognitive, behavioral, sensory, motor and autonomic processes.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Karuna Therapeutics Inc revenues increased from $0K to $37M. Net loss increased from $68.6M to $143.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase from $32.3M to $98.7M (expense), General and administrative - Other increase from $6.5M to $25.2M (expense).

    Industry: Bio Therapeutic Drugs

    99 High Street
    26th Floor
    BOSTON
    MASSACHUSETTS 02110
    US

    Income Statement

    • Annual
    • Quarterly

    News

    Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

    Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

    07:56, 17 April 2024

    US Earnings Season : JP Morgan, Citigroup, Wells Fargo

    The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

    16:03, 11 April 2024

    Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

    The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

    09:22, 11 April 2024

    US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

    US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

    15:11, 9 April 2024

    How escalating geopolitical tensions are impacting oil markets

    The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

    13:34, 4 April 2024

    A way forward: a roundup of recent central bank decisions

    Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

    12:47, 22 March 2024

    Bank of Japan Preview: will the BOJ end negative interest rates?

    The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

    08:44, 18 March 2024

    People also watch

    US100

    17,019.00 Price
    -2.000% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 21:00 (UTC)
    Spread 1.8

    XRP/USD

    0.51 Price
    +0.530% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01168

    BTC/USD

    64,303.70 Price
    +1.270% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 106.00

    Gold

    2,392.73 Price
    +0.610% 1D Chg, %
    Long position overnight fee -0.0192%
    Short position overnight fee 0.0110%
    Overnight fee time 21:00 (UTC)
    Spread 0.30

    Still looking for a broker you can trust?

    Join the 610,000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading